编者按：2024年美国临床肿瘤学会（ASCO）年会即将于当地时间5月31日至6月4日在芝加哥隆重召开。4月24日晚，ASCO年会摘要标题已率先震撼发布！此次盛会中，消化肿瘤领域大放异彩，口头摘要和临床科学研讨会摘要共计42项。其中，中国专家以卓越的表现贡献了16项，占比近半。特别值得一提的是，在这16项中国贡献的口头摘要中，北京大学肿瘤医院表现尤为突出，贡献了高达7项，而中山大学肿瘤防治中心也紧随其后，贡献了3项。这一卓越的成绩充分展现了中国研究在国际舞台上的重要影响力！现在，就让我们一起深入看看这些令人瞩目的研究成果吧！
北京大学肿瘤医院7项
口头摘要3项
1.摘要号：2501laudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: Final results of CT041-CG4006 phase 1 trial.
Claudin18.2靶向嵌合抗原受体T细胞治疗胃肠道癌症患者：CT041-CG4006 I期试验的最终结果讲者：齐长松 北京大学肿瘤医院2.摘要号：2504
Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies.
抗CCR8单克隆抗体LM-108联合抗PD-1抗体治疗胃癌患者的有效性和安全性：I/II期研究结果讲者：Chang Liu 北京大学肿瘤医院3.摘要号：3008
Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.
KRAS p.G12C抑制剂(glecirasib，JAB-21822)联合SHP2抑制剂(JAB-3312)治疗KRAS G12C突变实体瘤患者的最新安全性和有效性数据讲者：赵军 北京大学肿瘤医院快速口头摘要4项
4.摘要号：2518Phase I study of GUCY2C CAR-T therapy IM96 in patients with metastatic colorectal cancer.
GUCY2C CAR-T疗法IM96应用于转移性结直肠癌患者中的I期研究讲者：齐长松 北京大学肿瘤医院5.摘要号：3012
Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors.
I/II期MHB088C研究结果：新型B7H3 ADC，结合强效DNA拓扑异构酶I抑制剂治疗复发或转移性实体瘤讲者：沈琳 北京大学肿瘤医院6.摘要号：4012
Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer who failed immunochemotherapy: A multicenter, double-blind, randomized trial.
卡度尼利单抗联合pulocimab和紫杉醇作为免疫化疗失败的晚期胃或胃食管交界处(G/GEJ)癌症患者二线治疗的疗效和安全性：一项多中心、双盲、随机试验讲者：张小田 北京大学肿瘤医院7.摘要号：11518
Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST)
NB003(一种广谱KIT/PDGFRα抑制剂)在晚期胃肠道间质瘤(GIST)患者中的I期研究讲者：李健 北京大学肿瘤医院中山大学肿瘤防治中心3项
口头摘要2项
1.摘要号：3505Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study.
高度微卫星不稳定/错配修复缺陷型结直肠癌患者接受IBI310(抗CTLA-4抗体)联合信迪利单抗(抗PD-1抗体)新辅助治疗：来自一项随机、开放标记、Ib期研究的结果讲者：徐瑞华 中山大学肿瘤防治中心2.摘要号：11502
Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma
olverembatinib(HQP1351)在酪氨酸激酶抑制剂(TKI)耐药的琥珀酸脱氢酶(SDH)缺陷的胃肠道间质瘤(GIST)和副神经节瘤患者中的最新疗效结果讲者：邱海波 中山大学肿瘤防治中心快速口头摘要1项
3.摘要号：6013Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors.
pucotenlimab联合表皮生长因子受体-抗体药物偶联物(EGFR-ADC)MRG003治疗EGFR阳性实体肿瘤患者的I/II期研究初步结果讲者：阮丹云 中山大学肿瘤防治中心国内其他医院6项
快速口头摘要4项
1.摘要号：2519Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study.
IBI389，一种抗CLDN18.2/CD3双特异性抗体，在实体瘤、胃或胃食管肿瘤患者中的安全性和初步疗效结果：一项I期剂量递增和扩展研究讲者：Li Zheng 四川大学华西医院2.摘要号：LBA3511
Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial.
全程新辅助治疗联合长程放疗对比同步放化疗应用于高危局部晚期直肠癌(TNTCRT)：一项多中心、随机、开放标签的III期试验讲者：Xin Wang3.摘要号：3516
Three-year disease-free survival after transanal vs. laparoscopic total mesorectal excision for rectal cancer (TaLaR): A randomized clinical trial.
经肛门切除对比腹腔镜直肠全系膜切除术后，直肠癌患者的三年无病生存率(TaLaR)：一项随机临床试验。讲者：康亮 中山大学附属第六医院4.摘要号：4019
Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC).
C-CAR031，一种GPC3特异性TGFβRIIDN的自体armored-CAR-T，应用于晚期肝细胞癌(HCC)患者的I期研究讲者：章琦 浙江大学医学院附属第一医院临床科学研讨会摘要2项
5.摘要号：4009Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS).
维迪西妥单抗(RC48)联合替雷利珠单抗和S-1作为HER2过表达的晚期胃或胃食管交界处腺癌患者一线治疗的疗效：一项多中心、单臂、II期试验(RCTS)讲者：刘联 山东大学齐鲁医院6.摘要号：4011
Safety and efficacy of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: Preliminary results from a phase 1 study.
抗CLDN18.2/CD3双特异性抗体IBI389治疗晚期胰腺导管腺癌患者的安全性和有效性：I期研究的初步结果。讲者：郝继辉 天津医科大学肿瘤医院
